- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishes Adv$≤anced Oncology Profiling Cascade ★ with ProQinase to Progress its Porσ'¶ tfolio of Epitranscriptomic Drug Candidates
Gotham Therapeutics Est¶©ablishes Advanced Onco≠γlogy Profiling Casca™$≥δde with ProQinase to Prog ≈≥"ress its Portfolio of Epitranscriptomic Drug C©☆<£andidatesWEDNESDAY, OCTOBER 30, 2019Gotha§> δm Therapeutics, a biotechnology compan>≤↓£y developing a novel drug class targeting R<∑NA-modifying proteins, and ProQinase,γ£ an early stage drug-discovery co>←mpany, recently acquired by Malvern/P "¶A-based Reaction Biology"γ Corp., today announced that ←♦↕they have established an array ∑β↔of advanced biochemical and cellular assays t<>↕o characterize epitranscriptomic-d♦irected compounds.“Establishing tailore±↓d target engagement, ce★✔¥ll biology, phenotypic, and in-v>•ivo assays to evaluate compounds o✘♠>riginating from our three most advanced epi←εδΩtranscriptomic programs in parallel isδ≠ a crucial next step to develop our broλγ"ad pipeline towards the clinic,” said Dr. Gerh∞> ard Müller, Chief ScientificΩ€Ω∞ Officer of Gotham Therapeutics. “By pur∑€₩←suing the full range of the reader-write ∞r-eraser continuum, w↕λ≤e are able to focus on targe₹↕ts with the most compelling links to diseas™∏e and advance those programs in taΩ↕ε™ndem.”“Combining our high proficiency in prov☆ iding customized solution∏±'"s as early stage drug-discovery services, includi∞≈φng tailor-made biochemic γ♦≥al and cell-based assays, with Go'<₹tham’s expertise in epitranscriptomics, wΩ↔γ♥e were able to establish in a very↕ε short time a set of customized →ε↕enzymatic and cellular assays for compoun→πds addressing three different mRNA-modifying targ→δ€Ωets,” said Dr. Sebastian Dempe, Chief ε←₩↑Executive Officer of ProQinase. “We look forwπ&ard to supporting Gotham as the compan₽$♦y advances its prograπ"γms into lead optimization and t♥πo continued work with th>e Gotham team assisting the company to ≤ advance its broad pipeline in a time-effect>αive manner.”In addition to establ§∑ishing a tailor-made profiliδ'§✘ng cascade for compounds from♠σ↕ its three most advanced programs, Got♥♥≠ham has also made progress in strengthening→∑ its drug discovery eng★₩ine and developing it ♣¥s candidate base. Got☆¶®ham previously completed the gene-to-lead ph ↔ase for its drug discovery ÷®¥project targeting the METTL3/METTL1¥§" 4 complex and established a robust disc≤&overy process as a platfφ↕©orm for future projects. TheΩ∏ company has also generateε×d a library of high-quality coδmpounds tailor-made for★®<σ accelerated hit generation and hit-to™ >✘-lead expansion against÷₩¶ large parts of the epitranscriptomic target spa₹∞ce. This library includes a collectio←←≥™n of over 2,000 analogues covering over 80 distin÷♦♦ct chemotypes that will be used to further accel'→★erate Gotham’s drug disc π♣"overy efforts as it ex×Ωφ£pands its pipeline.The origi♥₹βnal link:https://www.pharmafocusasia≈.com/news/gotham-therapeutics-esta↑®↔ blishes-advanced-onco•Ω₹logy-profiling-cascade-with-proqinase-to-prπ₹ogress-its-portfolio-of-→★≥↑epitranscriptomic-drug§₩-candidates2019 Asia-paci<☆ fic pharma IP Leader Summit: http://en.zenseegrou€₩p.com/p/510934/will be held in Bei∑↕jing on Nove<₹&mber 14-15, and will attract more>→∏ than 500 industry experts♠®δ✔ from domestic and foreign pharm≈β≠aceutical companies, biotechnology comp↔☆anies, governments, associations, law firms, i×Ω§ntellectual property agents >€©and other companies to attend.Officπial registration and consultation channe™♥×αls:Contact：AnnPhone: 021-65♠∑650305Email：Marketing@zenseegroup.c↔'omhttp://en.zenseegroup.com/p/510934 -
1030
Gilead and Glympse B¥§®™io Announce Strategic Col↑♠laboration for Use of Biomarker Techno →logy in NASH Clinical Development
Gilead and Glympse Bio An★£↕∏nounce Strategic Collaboration for Use of Biomarkφ₩✘€er Technology in NASH Clinical DevelopmentTUESD≤"≥AY, OCTOBER 29, 2019Gilead Sciences Inc. and Gly≥×™mpse Bio, Inc., today announced that ♣≈§'the companies have entered in☆$✘to a strategic collaboration in nonalco "×holic steatohepatitis (NASH) clinγ↔ical development. Glympse Bio’s proprietaφ∑ry synthetic biomarkers – bioengineered ✔'to identify stage and'§" progression of disease as•±✘ well as early detection of tr≠∑±eatment response – will be &used to determine clin©πλical trial participants’ stage of disease at×®♠÷ initial screening and to determine responses to¥Ω∏ study treatment in Gilead’s NASH clinical p₽♦φrogram.“We are excite♦φd about the opportunity to pa ↔₽rtner with Glympse Bio to help infor✔&∑↓m our NASH development progr ₩εam,” said Mani Subramanian, M♥♠D, PhD Senior Vice President, Liver Diseases, G→♥ilead Sciences. “By utilizing this innβ¶>ovative technology, we hop♣÷e to better characterize this complex disease aλα↑nd improve our understanding of how our compoun∑¥ds impact disease progression≥™•←.”Glympse Bio’s propri><★₩etary technology, Glympse Inside™, combines s↕λ≥ynthetic biomarkers with machine learning apβ♣€proaches to identify the stage and m✘$onitor progression of important, complex di←←>πseases such as cancer, fibrosi$>©↑s, inflammation, and infections, in '$•'real time.“We are ver'&y excited about partner©®∑Ωing with Gilead, a leader in dr₹ Ωug development, to help drive earlier and mo™±re favorable outcomes for patients,” said Carolin>®e J Loew, President and CEO,↕★ Glympse Bio. “Gilead’s commitment to developi↓¶≠ng innovative medicines in a ε✘αreas of high unmet medical need al ≈€£igns with our mission of transforming d₩↕Ω♦isease detection and meas©♠<♥uring treatment response, all with the go σal of helping improve the lives of patieγπnts.”information source:pharma focus AsiaT₽→" he original link:https:https:htt>Ω≥λps://www.pharmafocusasia.com/news/gilead-and-glyπ≈∏>mpse-bio-announce-strategic-collaborati₽₩¥on-for-use-of-biomarker-technology-in-nash-"₽clinical-development2019 Asia-paci®∏fic pharma IP Leader Summit:∞ε♥http://en.zenseegroup.com/p/510934/ will be λλheld in Beijing on No>©≠•vember 14-15, and will attract more than 50₽α 0 industry experts from domestic and f₩≈oreign pharmaceutical companies, bio¥&λtechnology companies, governments, associations,♠ law firms, intellectual σ≈property agents and other companiesΩβ to attend.Official registration and c$©onsultation channels:Contact"∏✔♠：AnnPhone: 021-65650305Email：Marketing@ze§±nseegroup.comhttp://en.zenseegrλ♦π¶oup.com/p/510934 -
1029
HistoIndex Announces← Global Partnerships To Expand AI-Based Dβ∞λigital Pathology Platfor$m
HistoIndex Announces Global Partnerships To Ex"'€∞pand AI-Based Digital Pathology PlatformMOND♠₹AY, OCTOBER 28, 2019His×✔☆×toIndex announces the expan''✘sion of its AI-based digital pathology ₹¶∞platform towards large-scale NASH preclinical pro£®§'grams for pharmaceutical and biot™★ech companies to achie≠↕ve quantifiable and repro¥ ducible data on therape♠Ω↑€utic responses in NASH animal models, and to a •σ id CROs as well as research agenc★ε∑>ies in validating new models mimicking the NAS <€₹H disease.Published preclinical studies ha¥ ve demonstrated the use of HistoIndex's fully qua✘δntifiable Second Harmonic G →eneration (SHG) technolo< gy as a highly accurate stain ✘×-free method that can monitor thα®e efficacy of various th≤♥erapeutic agents, by q∞©→uantifying more than 450 NASH-associated parameteΩφrs in fibrosis, inflam ₩↕§mation, ballooning and steatosisΩ→☆•. The information of ✔∑these NASH-associated parameters gathered from the entire liver tissue, provides comprehenλ sive insights on the mechanism of actio>∞n of the therapeutic ÷<♦agent. As a drug di &±∑scovery tool, HistoIndex's SHG-enabled d₩✘igital pathology plat∞₩ "form will allow pharm∏∞≥aceutical and biotech companies to se♠ lect promising lead c₹€andidates for further optimization and make ÷¶informed decisions in☆$☆↕ the management of their NASH drug develo≈©✘pment pipeline.In addition©↔ to ongoing NASH clinical trials, HistoIndex♦<✔ is currently involved in multipl←λ$e preclinical studies, most of which are con≈$☆ducted by major pharmaceutical and bi∑β≠±otech companies, medical univ™φ✘♣ersities, CROs and reα✔search agencies. Notably, HistoIndex has recentl∑φσy entered into a colα←£laboration with the A*ST®$AR's Genome Institute of S∑≤ingapore (GIS) to val←→ idate their in vivo and in vitro NA✔ ♦≈SH models based on Asian-centric≈← clinical data. Says Professor Patrick Tan, Exec©δ©utive Director of the Genome Institute of ♦&✔'Singapore (GIS), "At GIS<≥↔↕, we conduct our preclinical studi >€es on fatty liver involv'♣ing data from animal models based on patient -derived transcriptomic data. This has ¶✔®a high translational potential as iδ ↔t helps us to pinpoint new therapeuti¶¥<Ωc targets and their validation. Therefoσ♠re, using a fully quanti∞↕tative, reliable and ob↕&π&jective pathological evaluation ↕σ≤€such as HistoIndex's AI-based digital patholo∑¶& gy platform is essen↔←&tial to the success of our efforts in th®¶erapeutic target discovery." '£HistoIndex is also a partner with globally-reε•φnowned CRO, WuXi Apptec, in advan ε>cing their NASH preclinical pr↕♦♦δograms with advanced R&D and smart ♣ •&imaging analysis capabilities. Publ♦♣αφished study data will be±δ§ available for discussions during ★₹€networking opportunities throughout σ™AASLD's The Liver Meeting® in November 2019. &↔Ω£nbsp;"We are very excit≤βed to extend our AI-based SHG™↔ platform to preclinical studies φto help companies with drug discov£™ery programs select promising ∏α lead candidates for further optimizati£€on and subsequent clinical deve±>®♣lopment," says Dr Poon Thon←∏g Yuen, Chief Executive Officer of Histβ™→oIndex. "Our SHG ima☆↓™≠ge analysis platform ×&has already been used to analyze the'¶¶≤ efficacy of a series ₩♠of promising drug candidates for →¥$♦NASH within various animal models commonl↔α≈→y-used by the industry, and we bel↕₹↔×ieve these preclinical part€↕♥>nerships will help drive the adoptio•♥n of our platform significantly."∑≠information source:pharm•$a focus AsiaThe original l¥§λink:https:https://www.phδ≈♠armafocusasia.com/news/histoindex≠λ-announces-global-partnerships-to-expand-ai-b★∞←ased-digital-pathology-platform2019 Asia-p∑λπacific pharma IP Leader Summit: http://en→™&.zenseegroup.com/p/510934/wilε₹l be held in Beijing®® on N¥ ovember 14-15, and will attract more∑"≈ than 500 industry experts from domesti☆∏c and foreign pharmaceutical companies, bi±∏↑otechnology companies, governments, associa€"tions, law firms, intellectual property →≠↑™agents and other companies to →δattend.Official registration and con≈±₩≤sultation channels:Coβδntact：AnnPhone: 021-656503₩ ±≥05Email：Marketing@zenseegroup.comhttp://enπ≥.zenseegroup.com/p/51♦≠↑←0934 -
1028
AVROBIO Receives Orphan-Drug Designation >÷₹from the U.S. FDA for AVR‑RD‑02 for the Tre™>atment of Gaucher Dise←€∑ase
AVROBIO Receives Orphan-Drug Designation from ₽"the U.S. FDA for AVR‑RD♦$'‑02 for the Treatment of Gaucher <≈♣DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc♦ >., today announced that the U.S. Food and Dr☆π↓ug Administration (FDA) has granted orβ♠phan-drug designation for the Company’s §∏investigational gene ther✔>β©apy, AVR-RD-02, for the treatment of Gaucher dis★εease. AVR-RD-02 consists of the patient’s o¶wn hematopoietic stem cells, genetical>≥<ly modified to express ←₩φglucocerebrosidase (GCase), the enzyme that∏™δδ is deficient in Gaucher disease. The Compan₹÷αy is actively recruiting in Canada for its Phase $γ1/2 clinical trial of AVR-RD-02, which seeks★✘≈± to evaluate the saf€↕ety and efficacy of the therapy in patie≠✘nts with Type 1 Gaucher disease.“Unde< <r the existing standard of care, pa§♠₽tients with Gaucher disease are bound to a ×↑"λlifelong infusion schedule≈ of enzyme replacement therapies, and st¥£↔ill experience painf÷"§ ul and progressive symptoms such as debilitati™₹$ng musculoskeletal p ♦ain and fatigue,” said Birgitte Volck, ♠'↑ MD, PhD, President of R ★×φesearch and Development a✘©↕t AVROBIO. “Orphan-drug designation recognizes≈<λ the unmet need of pop ✘ €ulations with rare diseasesε♠'$ like Gaucher where AVROBIO strives to transf∑β±orm lives by addressing the underlying cause of ¶ the disease with a single dose of gene tβ herapy.”Orphan-drug designati§☆βon is granted by the FDA to drugs and biologics ↕§✔γwhich are intended f×≠™≈or the safe and effective treatment, diagn≤♣≤₽osis or prevention of ra∏★∞☆re diseases or conditi•<®♠ons that affect fewer t&¥¥han 200,000 people i±₩n the United States. Orphan-drug designation prov§↓δides certain incenti→Ωves, which may include tax credits towarλ ds the cost of clinical trials and prescription d™"$δrug user fee waivers.∑♥information source:pharma focus As¥≤≠iaThe original link:https:https:≤α©//www.pharmafocusasi≠±a.com/news/avrobio-receives✘✘ $-orphan-drug-designation-from-¶☆↑<the-us-fda-for-avrrd02-for↕≈-the-treatment-of-gaucher-disea₽÷≠se2019 Asia-pacific phar≤β ma IP Leader Summit: http://en∞↕.zenseegroup.com/p/510934≈αλ≤/will be held in Beijing on&nΩ bsp;November 14-15, and will attract m£₽✔÷ore than 500 industry expσ erts from domestic and foreign pharmaceutδ<♣™ical companies, biotechnology c¶♦♥ompanies, governments, ass÷γociations, law firms, intellectual property ≤≤•agents and other companies to attend.Of≠¶ficial registration and consultation channelsε♦↑:Contact：AnnPhone: 021-6565§$0305Email：Marketing@zenseegrou≈"÷γp.comhttp://en.zenseegroup.com/p/510934≠♦ -
1026
AZTherapies Strengthens Neuroinf✘↔"lammation-Targeted Pipeline Through Acquisition ↕↓∏≤of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies, ¥Inc., a biopharmaceutical compa☆♦σ✘ny developing therapeutics to extend brain healt δ>h, today announced the acquisition of Smith>¶ → Therapeutics, a private biopharmaceutical com™✔$pany with a shared goal of targeting ¥×neuroinflammation to treat neurodegenera×$÷tive disease. Smith Therapeutics’γγ Founder and Chief Exe×≤←₩cutive Officer Philip Ashton-Ric☆✔kardt, Ph.D., has joined the senior leadershi₽$∑p team at AZTherapies as Senior Vice Pre•≠'•sident of Immunology. Financial terms £ •of the acquisition weδ¥≥re not disclosed.Smith Therap™δ×eutics’ proprietary research platform focuses o≠✘ n the use of modified T cells t←'¥o restore a healthy balaε≈φnce of inflammatory and regulatory cells÷ ' in the brain. To date, Smith¥≈> has successfully engine$&ered immunosuppressive T ✔↑♦regulatory (Treg) cells w •δ§ith Chimeric Antigen Receptors (CARs) targeti ≈ 'ng brain glial cells. Previous research Ω↔≤has demonstrated the ability o®™₹f Tregs to dampen microgl☆ial activity and reduce neuroinflammation i♣☆≤n models of neurodegeneration, suggestiφ≠↑ng their potential utility$§ in the treatment of diseases includi$∞★ng Progressive Supranuclear Palsy↓§≤ (PSP), Alzheimer’s disease, ≥ΩπParkinson’s disease, Huntington’s disease ÷, Amyotrophic Lateral Sclerosis♠♥ (ALS), and others.“This acquisition rΩ¶ epresents a meaningful step forwa>×≥rd for us as we continue to strengthen o↓$ur leadership position in the dev™ ×→elopment of therapies targeting neuroi®♦↕nflammation to stop or slow the progression of σΩneurodegenerative diseases,” said David R. ≈>Elmaleh, Ph.D., Founder, CEO, and Cha<δirman of AZTherapies. “We are exci"Ωφσted to be working with Philip as we add this cuttβ'ing-edge technology to our portfolio of iε ≈nnovative programs. An esteemed immunol ¥✔ogist and inventor of the technolo↑gy, Philip brings unparal±•<leled expertise to the±☆ company and we look forward to advanc₩δing this CAR-Treg program further into IND-®σ♣enabling studies and into clinical developmen>'≥t as rapidly as possible.”Dr. Ashton-Rickar₩ dt commented on the a✘<→λcquisition and his appoint¶∞♦ment: “Our shared rationale of targeting α¥neuroinflammation as the root cause of neurod<©✘egenerative disease makes this acqui "≤÷sition a great strategic fit for us. With AZ®™↓Therapies’ expertise in dφ♥δrug development and c↓←≥linical trial execution∞σ, we believe that together, we are well posit↕ ☆εioned to advance our CAR-Treg technology and fu↔€×ndamentally change neurodegenerative disease ¶♦↑progression.”Prior to launching Smit★πh Therapeutics in 2017γ∏, Dr. Ashton-Rickardt was Chair in Immunolog₹≈y at Imperial College London, €↕ Visiting Professor, Brigham>★Ω and Women’s Hospital, Har®•↑vard Medical School, and Asso®≠ciate Professor in the Department of P∑¥↑<athology at the Universit<©±☆y of Chicago. His work has been¶ & recognized by his peers through the award ≥♠ of tenure from The University of Chicagoσ>∞♣ and by his fellow citizens as a recipient of the← Early Career Award for Scientists and Enginee✘×✔♥rs from President Bil'♣l Clinton. He has pu±≠Ωblished more than 65 peer-reviewed papers in mor↑∞∏✔e than 30 academic journals (including Cell, Sci¶✔≥←ence, Immunity, and Nature Immunol↔☆ogy), has served as an editor for several ac<≠≥αademic journals, and has been α₩a member of grant review★☆ boards globally. Dr. Ashton-Rickar↕♦>dt received a B.Sc. in Biochemistr&<♠ y from the University of Lon±÷don, King’s College with honors, a Ph.D. ®♦←in Molecular Biology from t€he University of Edinburgh, and complΩ•βeted post-doctoral work at the ←&>University of Edinburgh and the Massachuset↑×ts Institute of Techno&∞$₽logy in Molecular Biology and ↔Molecular Immunology, respec♠↔∞tively.information source:÷✔✔σpharma focus AsiaThe origina×>₩l link:https:https://www.pharmaf♠↑↓ocusasia.com/news/aztherapies-strengtheε ×&ns-neuroinflammation-targeted-pipeline-throug&→h-acquisition-of-smith-therapeutics©♣$2019 Asia-pacific pharma IP Leader Summit: http≈₽≠¶://en.zenseegroup.com/p/510934/will b♦αe held in Beijing on Novembe£♣•πr 14-15, and will attract more than 500 i↑§>★ndustry experts from£★ domestic and foreign phar $✔≠maceutical companies, biotechnolog÷↔☆≥y companies, governments'↕λ, associations, law firms, intellect™÷ual property agents and other companies to aεδ×πttend.Official registration γ₽and consultation chan♠β♥nels:Contact：AnnPhone: 021-65650305Email≈₹↑≠：Marketing@zenseegroup.comhttp://e ≥§'n.zenseegroup.com/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016